Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CCR10 | P46092 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9621330 | 0.94 | KMT2A (0.45) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL6236946 | 0.90 | KMT2A (0.42) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL296256 | 0.87 | KMT2A (0.40) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL5050584 | 0.86 | LMNA (0.49) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL294590 | 0.84 | CYP3A4 (0.44) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL7206704 | 0.83 | KMT2A (0.42) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL9318067 | 0.83 | KMT2A (0.45) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL7206685 | 0.83 | KMT2A (0.42) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL7206960 | 0.83 | KMT2A (0.42) | LMNATHRBCYP2C19KMT2ACYP3A4 | |
| SCHEMBL9408110 | 0.82 | KMT2A (0.44) | LMNATHRBCYP2C19KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128140-B1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128140-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | Pola Pharma Inc. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1218351-B1 | NITROIMIDAZOLE DERIVATIVE AND DIAGNOSTIC IMAGING AGENT CONTAINING THE SAME | POLA CHEM IND INC (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-6743925-B1 | FLUORINE RADIOTAGGED; DETECTION OF CANCER CELLS OR ISCHEMIC SITES OF CIRCULATORY ORGANS | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2004-06-01 | — | — | US | disclosed |
| EP-1218351-A2 | NITROIMIDAZOLE DERIVATIVE AND DIAGNOSTIC IMAGING AGENT CONTAINING THE SAME | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001019799-A2 | NITROIMIDAZOLE DERIVATIVE AND DIAGNOSTIC IMAGING AGENT CONTAINING THE SAME | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | GALK1, HOGA1, DERA | LMNA 2553/4885THRB 3406/4885CYP2C19 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.